Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Coenzyme_A. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.99 |
| ▸ | AURKA | O14965 | 2/20 | 0.99 |
| ▸ | CHAT | P28329 | 2/20 | 0.99 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.99 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.99 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.99 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coenzyme_A SCHEMBL30334942 | 0.99 | EP300 (0.98) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL29778253 | 0.99 | EP300 (0.98) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL30630293 | 0.99 | EP300 (0.98) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18033983 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL26753 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18682057 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL13500623 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL26752 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18675521 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 | |
| Coenzyme_A SCHEMBL18682056 | 0.99 | EP300 (1.00) | EP300AURKACHATNAA50KAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117837752-A | A black ginseng product with high content of ginsenoside and its preparation method | 吉林明心堂生物科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | AMGEN INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-120060288-A | Blood-activating pellet 4-coumarate-CoA ligase gene Gl4CL, coded product and application thereof | 安徽中医药大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-115960149-B | Refining method and synthesis method of coenzyme A cysteamine impurity | 上海上药第一生化药业有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | disclosed |
| CN-118119386-A | Functionalized carboxylic acids and their use for treating diseases | 埃斯佩尔维塔治疗股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11667949-B2 | Reporter construct and biosensor for interferon second messenger 2-5A | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4065223-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022159808-A2 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022159811-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-114728167-A | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114686547-A | Method for enzymatic synthesis of acetyl coenzyme A by taking diacerein as donor | 中国医学科学院药物研究所 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | EP300 2058/4885AURKA 3082/4885CHAT 2435/4885 |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | EP300 1214/4885AURKA 3203/4885CHAT 750/4885 |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | SCD5, SCD, FADS2 | EP300 2061/4885AURKA 3067/4885CHAT 2060/4885 |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | EP300 2061/4885AURKA 3067/4885CHAT 2060/4885 |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | EP300 1214/4885AURKA 3203/4885CHAT 750/4885 |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | EP300 1214/4885AURKA 3203/4885CHAT 750/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | EP300 2091/4885AURKA 3139/4885CHAT 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.